Biopharma · FDA Approvals · Stock

GLUE Monte Rosa

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, th…

Assets on file: MRT-8102

Start live analysis of GLUE Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for GLUE, including recently decided ones.

Nothing scheduled in this window.

Recent first-hand events

Every first-hand event for GLUE, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 1, 2026

11:38 AM

GLUEMonte Rosa

Monte Rosa Therapeutics Reports Positive GFORCE-1 Phase 1 Topline for MRT-8102 in ASCVD Risk Subjects

MRT-8102 achieved robust NEK7 degradation and normalized multiple key ASCVD pathogenic drivers (DAMPs, IL-1β, hsCRP, fibrinogen, Lp(a)) to healthy-volunteer levels in obese subjects with elevated CVD risk. The asset was safe and well-tolerated with no SAEs or increased infection risk. This topline outcome informs dose selection and enables planned Phase 2 starts in coronary artery disease (GFORCE-2, H1 2027), gout (GEMINI-1, Q4 2026/Q1 2027), and hidradenitis suppurativa (GALAXY-1, H1 2027).

Topline resultsSEC 8-K Open record